Dr. Ho is the Chief Medical Officer of Boston Pharmaceuticals.
He received his B.A. in biology from The Johns Hopkins University and his M.D. and Ph.D. (pharmacology) degrees from Yale University, then completed pediatrics residency at The Children’s Hospital of Boston followed by clinical fellowships in pediatric hematology/oncology at the Dana-Farber Cancer Institute and in clinical oncology and regulatory sciences jointly through the U.S. FDA and the NCI. He began his career in drug discovery and development at the Investigational Drug Branch of the Cancer Therapy Evaluation Program, NCI followed by positions of increasing responsibility at Novartis and DuPont Pharmaceuticals. He subsequently served as Senior VP of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline and VP of Oncology Clinical Development at Johnson and Johnson. He was co-Founder and President of BeiGene Ltd. and most recently served as the Chief Medical Officer for Epizyme Inc. where he led the company’s clinical development, translational research and regulatory affairs functions.
Over his career, he has been directly responsible for the first-time-in-human dosing of 18 anticancer agents and has overseen the development of over 60 hematology and oncology compounds in all phases of clinical trials. His work has contributed to ten NCE or biologics approvals to date: Gleevec®; Arranon®; Tykerb®; Promacta®; Votrient®; Synribo®; Tafinlar®; Mekinist®; Sylvant®; and Rydap®. He serves on the Scientific Advisory Board of Accent Therapeutics and Pediatric Cancer Working Group of the Cancer Moonshot Task Force.